Subject(s)
Aspergillus fumigatus/genetics , Galactose/analogs & derivatives , Invasive Fungal Infections/diagnosis , Invasive Fungal Infections/prevention & control , Mannans/genetics , Mucorales/genetics , Triazoles/administration & dosage , Aspergillus fumigatus/chemistry , Galactose/genetics , Humans , Invasive Fungal Infections/microbiology , Mass Screening/methods , Mass Screening/standards , Mucorales/chemistry , Real-Time Polymerase Chain Reaction , Retrospective StudiesABSTRACT
AIM: To carry out a cost-minimization analysis including a comparison of the costs arising from first-line treatment by trastuzumab plus docetaxel versus trastuzumab plus paclitaxel in patients with metastatic breast cancer. METHODS: All consecutive patients with human epidermal growth receptor 2-postive metastatic breast cancer who were treated at Besançon University Hospital and Saint Vincent private hospital between 2001 and 2010 by first-line therapy containing trastuzumab plus taxane were retrospectively studied. Economic analysis took into account costs related to drugs, hospitalization, and healthcare travel. RESULTS: Progression-free survival difference between the two treatments was not significant (p = 0.65). First-line treatment by trastuzumab plus taxane was estimated at approximately 68,000 (p = 0.74). The drug costs represented around 70-75% of the total cost, mainly related to the use of trastuzumab. CONCLUSION: Our economic analysis shows that although the costs of the two trastuzumab plus taxane regimens are similar, they may contribute to the on-going debate about the availability and use of innovative chemotherapy drugs, in particular in human epidermal growth factor receptor 2-positive metastatic breast cancer with new therapies such as trastuzumab-DM1 and pertuzumab.
